Allena Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference
May 30, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing...
Allena Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
May 08, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Initiated Phase 3 Study URIROX-1™ and Phase 2 Study 206 for ALLN-177 in Patients with Severe Hyperoxaluria -- -- Reiterates Guidance for Key Objectives Across Portfolio-- NEWTON, Mass., May 08,...
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
March 27, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
-- Initiated URIROX-1™, First Phase 3 Trial of ALLN-177 in Enteric Hyperoxaluria; Topline Data Expected in Second Half of 2019 – -- Initiated Phase 2 Trial of ALLN-177 for Patients with Primary...
Allena Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference
March 07, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
NEWTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing...
Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria
March 06, 2018 08:00 ET
|
Allena Pharmaceuticals, Inc.
URIROX-1TM is the Largest Controlled Trial of a Novel Therapeutic for this Underserved Patient Population - Topline Data Expected in Second Half of 2019 -ALLN-177 has Potential to be the First...
Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
December 14, 2017 07:00 ET
|
Allena Pharmaceuticals, Inc.
-- Successfully Completed Initial Public Offering, Raising $74.9 Million in Gross Proceeds -- Presented Final Results from Phase 2 Trials of ALLN-177 in Secondary Hyperoxaluria at ASN Kidney Week...
Allena Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
November 01, 2017 21:03 ET
|
ALLENA PHARMACEUTICALS, INC.
NEWTON, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme...